INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2012

Long-term use of standardized Ginkgo biloba extract did not reduce the risk of progressing to Alzheimer's disease in elderly adults with memory complaints.

In the GuidAge trial, 2,854 adults aged 70 years or older with memory complaints were randomly allocated to receive 120 mg standardized Ginkgo biloba extract (EGb761) twice daily or placebo for 5 years. By 5 years, probable Alzheimer's disease was diagnosed in 61 participants in the ginkgo group (1.2 cases per 100 person-years) versus 73 in the placebo group (1.4 cases per 100 person-years; HR 0.84, 95% CI 0.60-1.18; p=0.306). Incidence of adverse events, all-cause deaths (76 vs 82; p=0.68), stroke (65 vs 60; RR 1.12, 95% CI 0.77-1.63; p=0.57), and other hemorrhagic or cardiovascular events did not differ significantly between groups.

Study type
Randomized, parallel-group, double-blind, placebo-controlled trial
Who was studied
2,854 adults aged 70 years or older with spontaneous memory complaints in France
What was measured
Conversion to probable Alzheimer's disease over 5 years

THE PAPER

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial.

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S, GuidAge Study Group. Lancet Neurol, 2012.

PubMed 22959217 ↗DOI 10.1016/s1474-4422(12)70206-5 ↗

Brain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.